| Sep 16 |
Hope remains that Roche’s prasinezumab can overcome recent string of failures in Parkinson’s disease
|
| Sep 14 |
J&J leads H1 healthcare deals as Big Pharma dealmaking returns: report
|
| Sep 13 |
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
|
| Sep 13 |
Should You Buy Novavax Stock After This Regulatory Win?
|
| Sep 13 |
CD&R in Talks With Banks Over Debt to Fund Equity for Sanofi Arm
|
| Sep 13 |
Sanofi signs radioligand therapy licensing deal for rare cancers
|
| Sep 12 |
Sanofi in licensing deal for radiopharmaceutical for cancer
|
| Sep 12 |
Fulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key test
|
| Sep 12 |
Sanofi’s Phase III CSU treatment trial meets endpoints
|
| Sep 12 |
Press Release: Sanofi, RadioMedix, and Orano Med announce licensing agreement on next-generation radioligand medicine for rare cancers
|
